Loading...
•
Dec 31, 2024
Regeneron Q4 2024 Earnings Report
Regeneron's financial performance for Q4 2024 showed revenue growth, driven by key products like Dupixent and Libtayo, and the company initiated a quarterly dividend and increased share repurchase capacity.
Key Takeaways
Regeneron reported a 10% increase in revenue for Q4 2024, reaching $3.79 billion. GAAP EPS was $8.06, and non-GAAP EPS was $12.07. The company initiated a quarterly dividend program and increased its share repurchase capacity to approximately $4.5 billion.
Q4 2024 revenues increased by 10% to $3.79 billion compared to Q4 2023.
Dupixent global net sales increased by 15% to $3.70 billion compared to Q4 2023.
Libtayo global net sales increased by 50% to $367 million compared to Q4 2023.
The company initiated a quarterly cash dividend program and increased total share repurchase capacity to approximately $4.5 billion.
Regeneron
Regeneron
Regeneron Revenue by Segment
Regeneron Revenue by Geographic Location
Revenue by Segment
Net Product Sales Revenue
CapyFin.comRevenue by Geographic Location
U.S. Net Product Sales Revenue
CapyFin.com Forward Guidance
Regeneron provided financial guidance for 2025, including GAAP and non-GAAP estimates for R&D and SG&A expenses, gross margin on net product sales, COCM, capital expenditures, and effective tax rates.
Positive Outlook
- GAAP R&D is projected between $5.560 billion and $5.795 billion.
- Non-GAAP R&D is projected between $5.000 billion and $5.200 billion.
- GAAP SG&A is projected between $2.910 billion and $3.095 billion.
- Non-GAAP SG&A is projected between $2.550 billion and $2.700 billion.
- GAAP gross margin on net product sales is expected to be between 84% and 85%.
Challenges Ahead
- Non-GAAP gross margin on net product sales is expected to be between 87% and 88%.
- COCM is projected between $1.000 billion and $1.150 billion.
- Capital expenditures are projected between $850 million and $975 million.
- GAAP effective tax rate is projected between 9% and 11%.
- Non-GAAP effective tax rate is projected between 11% and 13%.